Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Bayer
Modality
UNKNOWN
Development Phase
Unknown
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02468102CT.gov Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden) | — | Completed | — | — | — |
NCT01947985CT.gov Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands) | — | Completed | — | — | — |
NCT01947959CT.gov Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany) | — | Completed | — | — | — |
NCT01947998CT.gov Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Coronary Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bay 59-7939 (this asset) | Bayer | Unk | D · 30 |
| Aspirin | Shanghai CureGene Pharmaceutical Co., Ltd. | P4 | BBB |
| Atorvastatin | Punjab Institute of Cardology | P4 | BB |
| Ticagrelor | Tianjin Institute of Pharmaceutical Research Co., Ltd | P4 | BB |
| Exenatide | Saint Luke's Health System | P4 | BB |
| Clopidogrel | Shanghai CureGene Pharmaceutical Co., Ltd. | P4 | BB |
| Rosuvastatin | Nanjing First Hospital, Nanjing Medical University | P4 | BB |
| Ezetimibe | Punjab Institute of Cardology | P4 | BB |
| Ferric Cation | Fundación para la Investigación del Hospital Clínico de Valencia | P4 | BB |
+26 more in the Acute Coronary Syndrome cohort
Other indications for Bay 59-7939
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Atrial Fibrillation | — | P3 | BB · 66 |
| Stroke Disorder | — | P3 | CCC · 52 |
| Pulmonary Embolism | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bay 59-7939 in Acute Coronary Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bay-59-7939-acute-coronary-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →